Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: The cumulative multicenter European experience

Annals of Surgery

Volumn 224, Issue 6, 1996, Pages 756-765

  Eggermont, Alexander M M ^a   Koops, Heimen Schraffordt ^b   Klausner, Joseph M ^c   Kroon, Bin B R ^d   Schlag, Peter M ^e   Liénard, Danielle ^h   Van Geel, Albertus N ^a   Hoekstra, Harald J ^b   Meller, Isaac ^c   Nieweg, Omgo E ^d   Kettelhack, Christoph ^e   Ben Ari, Gur ^g   Pector, Jean Claude ^h   Lejeune, Ferdy J ^f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e umboldt Universitat   (Germany)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g SHEBA MEDICAL CENTER   (Israel)

^h JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; DRUG EFFICACY; FEMALE; HUMAN; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; LIPOSARCOMA; MALE; MELPHALAN; MIDDLE AGED; SARCOMA; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0009885824     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199612000-00011     Document Type: Article

References (58)

1. Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clincopathologic staging for localized soft tissue sarcoma of the extremity:a study of 423 adults. J Clin Oncol 1992; 10:1317-1327.
2. Suit HD, Tepper JE. Impact of improved local control on survival in patients with soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1986; 12:699-700.
3. Brennan MF, Shiu MH, Collin C, et al. Extremity soft tissue sarcomas. Cancer Treat Symp 1985; 3:71-81.
4. Potter DA, Kinsella D, Gladstein E, et al. High grade soft tissue sarcomas of the extremities. Cancer 1986; 59:190-205.
5. Stotter AT, A'Hearn RP, Fisher C, et al. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 1990; 65:1119-1129.
6. Gustafson P, Rööser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 1991; 67:2083-2086.
7. Boring CC, Squires TS, Tong T, et al. Cancer Statistics, 1994. CA Cancer J Clin 1994; 44:7-26.
8. Suit HD, Proppe KH, Mankin HJ, et al. Preoperative radiation therapy for sarcoma of soft tissue. Cancer 1981; 47:2269-2274.
9. Eilber FR, Mirra JJ, Grant T, et al. Is amputation necessary for sarcoma: a 7-year experiment with limb salvage. Ann Surg 1980; 192:431-437.
10. Eilber FR, Morton DL, Eckhardt J, et al. Limb salvage for skeletal and soft tissue sarcomas: multidisciplinary preoperative therapy. Cancer 1984; 53:2579-2584.
11. Shiu MH, Hilaris BS, Harrison LB, et al. Brachytherapy and function-saving resection of soft tissue sarcoma arising in the limb. Int J Radiat Oncol Biol Phys 1991; 21:1485-1492.
12. Creech OJ, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148:616-632.
13. Benckhuijsen C, Kroon BBR, Van Geel AN, et al. Regional perfusion treatment with melphalan for melanoma in a limb: evaluation of drug kinetics. Eur J Surg Oncol 1988; 14:157-163.
14. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin comparred with that of melphalan and other drugs. World J Surg 1992; 61:227-233.
15. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977; 185:555-564.
16. McBride CM. Sarcomas of the limbs: result of adjuvant chemotherapy using isolation perfusion. Arch Surg 1974; 109:304-308.
17. Stehlin JS, de Ipolyi PD, Giovanella BC, et al. Soft tissue sarcomas of the extremity: multidisciplinary therapy employing hyperthermic perfusion. Am J Surg 1975; 130:643-646.
18. Lethi PM, Stephens MH, Janoff K, et al. Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 1986; 162:149-152.
19. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, et al. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 1987; 60:1703-1707.
20. Braat RP, Wieberdink J, van Slooten EA, et al. Regional perfusion with Adriamycin in soft tissue sarcomas. In: Schwemmle K, Aigner K, eds. Vascular Perfusion in Cancer Therapy, Recent Results in Cancer Research. Vol. 86. Berlin: Springer-Verlag; 1983:260-263.
21. Klaase JM, Kroon BBR, Benckhuysen C, et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989; 64:616-621.
22. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate of high grade limb sarcomas. Cancer 1994; 73:2140-2146.
23. Filippo FD, Calabro AM, Cavallari A, et al. The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcomas of the extremities. World J Surg 1988; 12:332-339.
24. Liénard D, Delmotte JJ, Renard N, et al. High doses of rTNF-α in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.
25. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathologic prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33:37-42.
26. Klaase JM, Kroon BBR, Van Geel AN, et al. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993; 80:1124-1126.
27. WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication No. 48, Geneva: WHO; 1979.
28. Wieberdink J, Benckhuijsen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905-910.
29. Wanebo HJ, Temple WJ, Popp MB, et al. Preoperative regional therapy for extremity sarcoma: a tricenter update. Cancer 1995; 75:2299-2306.
30. Rouēsse JG, Friedman S, Sevin DM, et al. Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas. Cancer 1987; 60:296-300.
31. 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose TNFα + melphalan isolated limb perfusion. NMR Biomed 1995; 8:215-224.
32. Nieweg OE, Pruim J, Hoekstra HJ, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma. J Nucl Med 1994; 35:90-92.
33. Thom AK, Alexander HR, Andrich MP, et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995; 13:264-273.
34. Swaak AJG, Liénard D, Schraffordt Koops H, et al. Effects of recombinant tumour necrosis factor (rTNF-α) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-α administration in isolated limb perfusions in cancer patients. Eur J Clin Invest 1993; 23:812-818.
35. Lejeune FJ, Liénard D, Eggermont AMM, et al. Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circ Shock 1994; 43:191-197.
36. Hill S, Fawcett WJ, Sheldon J, et al. Low-dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993; 80:995-997.
37. Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high dose tumor necrosis factor-α in combination with interferon-τ and melphalan for irresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653-2665.
38. Liénard D, Eggermont AMM, Schraffordt Koops H, et al. TNF in isolated limb perfusion for treatment of locally advanced melanoma. Eur Cytokine Netw 1996; 7:299 (abstract).
39. Manusama ER, Nooijen PTGA, Stavast J, et al. Synergistic antitumour effect of recombinant tumor necrosis factorα with melphalan in isolated limb perfusion in the rat. Br J Surg 1996; 83:551-555.
40. Posner M, Liénard D, Lejeune FJ, et al. Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic intransit melanoma. Proc Am Soc Clin Oncol 1994; 13:1351 (abstract).
41. Nooijen PTGA, Manusama ER, Eggermont AMM, et al. Synergistic effects of TNFα and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electronmicroscopical study. Br J Cancer 1996 (in press).
42. Manusama ER, Stavast J, Durante NMC, et al. Isolated limb perfusion in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 1996; 22:152-157.
43. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24 h intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80:1039-1044.
44. Blick MB, Sherwin SA, Rosenblum M, et al. A phase I trial of recombinant human tumor necrosis factor in cancer patients. Cancer Res 1987; 47:2986-2989.
45. Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously administered recombinant tumor necrosis factor alpha in cancer patients. J Clin Oncol 1988; 6:1328-1334.
46. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72:3666-3670.
47. Sugarman BJ, Aggarwal BB, Hass PE, et al. Recombinant tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230:943-945.
48. Renard N, Liénard D, Lespagnard L, et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high- dose tumour necrosis factor alpha (TNFα). Int J Cancer 1994; 57:656-663.
49. Renard N, Nooijen PTGA, Schalkwijk L, et al. VWF release and platelet aggregation in human melanoma after perfusion with TNFα. J Pathol 1995; 176:279-287.
50. Nooijen PTGA, Eggermont AMM, Verbeek MM, et al. Transient induction of E-selectin expression following TNF-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother 1996; 19:33-44.
51. Watanabe N, Niitsu Y, Umeno H, et al. Toxic effect of TNF on tumor vasculature in mice. Cancer Res 1988; 49:2179-2183.
52. Nawroth P, Handley D, Matsueda G, et al. TNF/Cachectin-induced intravascular fibrin formation in Meth-A fibrosarcomas. J Exp Med 1988; 168:637-647.
53. Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Angiographic observations before and after high dose TNF isolated limb perfusion in patients with extremity soft tissue sarcomas. Eur J Surg Oncol 1994; 20:323 (abstract).
54. Manusama ER, Stavast J, Marquet RL, et al. Total body irradiation (TBI) attenuates antitumor effects of TNFα in isolated limb perfusions (ILP) in the rat. Eur J Surg Res 1995; 27:110 (abstract).
55. Prograbniak HW, Witt CJ, Terrill R, et al. Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg 1994; 57:1477-1483.
56. Fraker DL, Alexander HR, Thom AK. Use of tumor necrosis factor in isolated hepatic perfusion. Circulatory Shock 1994; 44:45-50.
57. Vries de MR, Borel Rinkes IHM, Wiggers T, et al. Hyperthermic isolated hepatic perfusion with TNFα with and without melphalan in pigs. Eur J Surg Res 1995; 27:81 (abstract).
58. Veen van de AH, Manusama ER, Kampen van CA, et al. Tumor Necrosis Factor-α (TNFα) in isolated kidney perfusions in rats: toxicity and antitumor effects. Eur J Surg Oncol 1994; 20:404-405.